Skip to main content

Home/ Cancer/ Group items tagged pubmed medicinal

Rss Feed Group items tagged

Matti Narkia

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. -... - 0 views

  •  
    Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glode LM.
    A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.
    Invest New Drugs. 2007 Apr;25(2):139-46. Epub 2006 Nov 1.
    PMID
Matti Narkia

Prostate cancer chemoprevention by silibinin: bench to bedside. - Entrez PubMed - 0 views

  •  
    Singh RP, Agarwal R.
    Prostate cancer chemoprevention by silibinin: bench to bedside.
    Mol Carcinog. 2006 Jun;45(6):436-42. Review.
    PMID: 16637061 [PubMed - indexed for MEDLINE]
Matti Narkia

Prostate cancer prevention by silibinin. - Entrez PubMed - 0 views

  •  
    Singh RP, Agarwal R.
    Prostate cancer prevention by silibinin.
    Curr Cancer Drug Targets. 2004 Feb;4(1):1-11. Review.
    PMID: 14965263 [PubMed - indexed for MEDLINE]
Matti Narkia

Zyflamend((R))-Mediated Inhibition of Human Prostate Cancer PC3 Cell Proliferation: Eff... - 0 views

  •  
    Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA.
    Zyflamend((R))-Mediated Inhibition of Human Prostate Cancer PC3 Cell Proliferation: Effects on 12-LOX and Rb Protein Phosphorylation.
    Cancer Biol Ther. 2007 Feb 25;6(2) [Epub ahead of pr
Matti Narkia

Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induc... - 0 views

  •  
    Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R.
    Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression.
    Nutr Cancer. 2005;52(2):202-12.
    PMID:
1 - 5 of 5
Showing 20 items per page